Patients needing enteral nutrition suffer high intolerance rates from existing products without alternatives.
Developing more easily digestible and tolerable plant-based enteral nutrition products to improve patient well-being and health.
Anterra participated in the Series C financing round alongside Novo Holdings, Kaiser Permanente Ventures, Coefficient Capital, Aliment Capital, Eaglehead Capital, Main Street Advisors, and Goldman Sachs Asset Management.
Our other companies
Food marketplace helping people eat better effortlessly
Digital procurement platform for farm inputs and services
Innovative materials to extend fresh produce shelf life
Real-time data collection tools for farm machinery
Financial and data services for the fresh produce industry
Next-generation synthetic cellular controls
Drug discovery using machine learning
Genome engineering using CRSPR-Cas9
Novel flavor generation using modified brewer’s yeast
Microbiome innovation for animal health